Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer

Area of Science:

• Pediatric Oncology
• Pharmacology
• Hematology

Background:

• Pediatric acute lymphoblastic leukemia (ALL) cure rates approach 90% in developed nations.
• ALL treatment includes intensive chemotherapy followed by 24 months of maintenance therapy (ALL-MT).
• ALL-MT relies on daily oral 6-mercaptopurine (6MP) and weekly oral methotrexate (MTX).

Purpose of the Study:

• To review challenges and strategies for managing ALL maintenance therapy (ALL-MT).
• To emphasize individualized dosing of 6MP and MTX based on patient tolerance.
• To focus on the Indian context for ALL-MT management.

Main Methods:

• Review of current ALL-MT protocols and management strategies.
• Discussion of factors influencing drug tolerance (genetic and non-genetic).
• Highlighting the importance of clinical assessments and blood count monitoring.

Main Results:

• Suboptimal ALL-MT intensity correlates with inferior patient outcomes.
• Treatment interruptions due to non-adherence or toxicity can negatively impact results.
• Individualized dosing and close supervision are essential for effective ALL-MT.

Conclusions:

• Effective ALL-MT necessitates uninterrupted treatment at the highest tolerated drug doses.
• Management requires careful monitoring, dose adjustments, and minimizing treatment interruptions.
• Strategies for optimizing ALL-MT are critical, especially within the Indian healthcare setting.